Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective against homologous recombination-deficient (HR-) tumors.
• Homologous recombination-proficient (HR+) tumors, including high-grade serous ovarian cancer (HGSOC), are typically resistant to PARPi.
• The role of EZH2 in mediating PARPi resistance in HR+ HGSOC is not fully understood.

Purpose of the Study:

• To investigate whether functional silencing of EZH2 can sensitize HR+, CARM1-high HGSOC cells to PARPi.
• To elucidate the mechanism by which EZH2 silencing impacts PARPi sensitivity and cell death.
• To explore potential therapeutic strategies for overcoming PARPi resistance in ovarian cancer.

Main Methods:

• Functional silencing of EZH2 in HR+, CARM1-high HGSOC cell lines.
• Treatment of these cells with PARPi.
• Assessment of cell viability, cell death, and cell cycle progression, focusing on mitotic catastrophe.

Main Results:

• Functional silencing of EZH2 rendered HR+, CARM1-high HGSOC cells sensitive to PARPi.
• PARPi treatment induced mitotic catastrophe and subsequent cell death in EZH2-silenced cells.
• These findings highlight a novel mechanism of PARPi resistance and a potential therapeutic vulnerability.

Conclusions:

• EZH2 plays a critical role in conferring PARPi resistance in HR+ HGSOC.
• Targeting EZH2 in combination with PARPi may represent a viable therapeutic strategy for patients with HR+ ovarian cancer.
• Further research is warranted to translate these findings into clinical practice.